Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SCN9A | Q15858 | 1/20 | 0.47 |
| ▸ | JAK1 | P23458 | 1/20 | 0.46 |
| ▸ | PDE4B | Q07343 | 9/20 | 0.46 |
| ▸ | PDK4 | Q16654 | 1/20 | 0.46 |
| ▸ | PDE4A | P27815 | 3/20 | 0.44 |
| ▸ | PDE4C | Q08493 | 3/20 | 0.44 |
| ▸ | PDE4D | Q08499 | 3/20 | 0.44 |
| ▸ | CDK7 | P50613 | 1/20 | 0.43 |
| ▸ | CDK13 | Q14004 | 1/20 | 0.43 |
| ▸ | CDK12 | Q9NYV4 | 1/20 | 0.43 |
| ▸ | TBK1 | Q9UHD2 | 1/20 | 0.43 |
| ▸ | CNR1 | P21554 | 1/20 | 0.41 |
| ▸ | NAMPT | P43490 | 1/20 | 0.41 |
| ▸ | GRM5 | P41594 | 1/20 | 0.41 |
| ▸ | GRM1 | Q13255 | 1/20 | 0.41 |
| ▸ | HTR6 | P50406 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL27372084 | 1.00 | SCN9A (0.47) | SCN9AJAK1PDE4BPDK4PDE4A | |
| SCHEMBL31700764 | 0.81 | PDK4 (0.53) | SCN9AJAK1PDK4CNR1NAMPT | |
| SCHEMBL1038502 | 0.81 | PDK4 (0.52) | SCN9AJAK1PDK4CNR1NAMPT | |
| SCHEMBL19107666 | 0.80 | PDK4 (0.51) | SCN9AJAK1PDK4CNR1NAMPT | |
| SCHEMBL1764181 | 0.79 | PDK4 (0.53) | SCN9AJAK1PDK4CNR1NAMPT | |
| SCHEMBL1763861 | 0.79 | PDK4 (0.50) | SCN9AJAK1PDK4CNR1NAMPT | |
| SCHEMBL27372074 | 0.78 | PDE4B (0.56) | SCN9APDE4BPDE4APDE4CPDE4D | |
| SCHEMBL30755183 | 0.78 | PDE4B (0.56) | SCN9APDE4BPDE4APDE4CPDE4D | |
| SCHEMBL2951348 | 0.77 | NAMPT (0.60) | SCN9AJAK1PDK4CDK7CDK13 | |
| SCHEMBL2264033 | 0.77 | GABRP (0.60) | SCN9AJAK1PDK4CNR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260034123-A1 | CDK2 INHIBITORS AND METHODS OF USING THE SAME | CEDILLA THERAPEUTICS INC (US) | 2026-02-05 | — | — | US | disclosed |
| EP-4562016-A2 | CDK2 INHIBITORS AND METHODS OF USING THE SAME | Cedilla Therapeutics, Inc. (US) | 2025-06-04 | — | — | EP | disclosed |
| WO-2024026483-A2 | CDK2 INHIBITORS AND METHODS OF USING THE SAME | CEDILLA THERAPEUTICS, INC. (US) | 2024-02-01 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260034123-A1 | CDK2 INHIBITORS AND METHODS OF USING THE SAME | CDK2, CDK1, CDK20 | SCN9A 2743/4885JAK1 578/4885PDE4B 4728/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.